Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is currently conducting a long-term extension study titled A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren’s Syndrome (SS). The primary goal is to assess the safety and tolerability of the drug dazodalibep over an extended period, which is significant for understanding its long-term effects on patients with Sjögren’s Syndrome.
The study tests the drug dazodalibep, administered intravenously, to evaluate its effectiveness in treating Sjögren’s Syndrome. Participants who previously completed a 48-week treatment will continue for an additional 144 weeks, either continuing with dazodalibep or switching from a placebo to dazodalibep.
This interventional study is designed as a randomized, parallel assignment with double masking, meaning both participants and investigators are unaware of the treatment assignments. The primary purpose of the study is treatment-focused.
The study began on February 25, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 24, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Amgen’s stock performance, as positive results may enhance investor confidence and the company’s market position. Given the competitive landscape in autoimmune disease treatments, successful long-term data could differentiate Amgen’s offering from competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.